Related Experiment Videos
Rationale for testing thrombolysis in acute ischaemic stroke. MAST Group
1Department of Clinical and Biological Neurosciences, University Hospital, Grenoble, France.
Clinical Trials and Meta-Analysis
|October 5, 1993
Summary
Stroke patients face poor prognoses. Early thrombolytic therapy, like streptokinase, may improve outcomes, but trials need adequate methodology and sample size for clear answers on its efficacy.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Stroke is a leading cause of death and disability in developed nations.
- Hospitalized stroke patients have a high 30-day mortality rate (20-30%) and significant disability among survivors (30%).
- Early intervention is hypothesized to improve stroke patient prognosis, supported by animal studies.
Purpose of the Study:
- To assess the safety and efficacy of thrombolytic therapy using streptokinase in acute cerebral infarction patients.
- To address the inconclusive results from previous trials due to insufficient sample size or inadequate methodology.
Main Methods:
- The Multicenter Acute Stroke Trials (MAST) was designed to evaluate thrombolytic therapy.
- Focus on assessing safety and efficacy of streptokinase for acute cerebral infarction.
Main Results:
- Previous clinical trials on thrombolytic therapy for acute cerebral infarction yielded unclear results.
- Inadequacies in sample size and methodology of prior studies limited definitive conclusions.
Conclusions:
- Further well-designed trials are needed to establish the safety and efficacy of thrombolytic therapy for acute stroke.
- The MAST is designed to provide a clearer answer on streptokinase's role in acute cerebral infarction treatment.